Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to
differences in treatment outcome. Unbound drug concentrations are believed to be more …

Background The objective of the five clinical studies presented in this article was to
investigate the single-dose pharmacokinetics of gefitinib (IRESSA®, ZD1839), an epidermal …

A rapid, sensitive and specific method was developed and validated using liquid
chromatography–tandem mass spectrometry (LC/MS/MS) for determination of gefitinib in …

The relative distribution of gefitinib-related material in nude mice bearing sc human tumor
xenografts and in an orthotopic rat lung tumor model was investigated following oral …

1. The pharmacokinetics of gefitinib and its metabolites in rat and dog were investigated in
preclinical studies conducted to support the safety evaluation and clinical development of …

Gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, has been
developed and approved for treatment of advanced non-small cell lung cancer (NSCLC). In …

Desmethyl-gefitinib is a major metabolite of gefitinib observed in human plasma at
concentrations similar to those of gefitinib. The epidermal growth factor receptor (EGFR) …

Gefitinib (Iressa, AstraZeneca) has been widely used for the treatment of locally advanced or
metastatic non-small cell lung cancer. A number of studies have been reported on its …

Gefitinib and erlotinib are two oral tyrosine kinase inhibitors (TKI) approved for the treatment
of advanced non-small cell lung cancer (NSCLC). Published methods for simultaneous …

Purpose We investigated whether the pharmacokinetics and tolerability of gefitinib were
altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two …